These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. ENA oligonucleotides as therapeutics. Koizumi M Curr Opin Mol Ther; 2006 Apr; 8(2):144-9. PubMed ID: 16610767 [TBL] [Abstract][Full Text] [Related]
64. Expression of the integrin genes in the developing cochlea of rats. Toyama K; Ozeki M; Hamajima Y; Lin J Hear Res; 2005 Mar; 201(1-2):21-6. PubMed ID: 15721557 [TBL] [Abstract][Full Text] [Related]
65. Antisense inhibition of chondrocyte CD44 expression leading to cartilage chondrolysis. Chow G; Nietfeld JJ; Knudson CB; Knudson W Arthritis Rheum; 1998 Aug; 41(8):1411-9. PubMed ID: 9704639 [TBL] [Abstract][Full Text] [Related]
66. Locked nucleic acid: a potent nucleic acid analog in therapeutics and biotechnology. Jepsen JS; Sørensen MD; Wengel J Oligonucleotides; 2004; 14(2):130-46. PubMed ID: 15294076 [TBL] [Abstract][Full Text] [Related]
67. Antisense oligonucleotides fail to inhibit the expression of central beta adrenergic receptors. Zhang K; O'Donnell JM Res Commun Mol Pathol Pharmacol; 1997 Jan; 95(1):21-32. PubMed ID: 9055346 [TBL] [Abstract][Full Text] [Related]
68. Inhibition of Plasmodium falciparum hypoxanthine-guanine phosphoribosyltransferase mRNA by antisense oligodeoxynucleotide sequence. Dawson PA; Cochran DA; Emmerson BT; Gordon RB Mol Biochem Parasitol; 1993 Jul; 60(1):153-6. PubMed ID: 8366890 [No Abstract] [Full Text] [Related]
71. Effect of antisense inhibition of Urokinase receptor on malignancy. Ossowski L Curr Top Microbiol Immunol; 1996; 213 ( Pt 3)():101-12. PubMed ID: 8815000 [No Abstract] [Full Text] [Related]
72. Antisense oligonucleotides decrease expression of human CD46, a regulator of complement. Milland J; Loveland BE; Russell SM; McKenzie IF Transplant Proc; 1993 Oct; 25(5):2922-3. PubMed ID: 8212285 [No Abstract] [Full Text] [Related]
73. [Antisense oligonucleotides inhibiting ribosomal functions in mycobacteria]. Demchenko IuN; Zenkova MA; Vlasov VV Izv Akad Nauk Ser Biol; 2005; (2):133-40. PubMed ID: 16004273 [TBL] [Abstract][Full Text] [Related]
74. Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming. Saetrom P Bioinformatics; 2004 Nov; 20(17):3055-63. PubMed ID: 15201190 [TBL] [Abstract][Full Text] [Related]
75. Critical issues in the antisense inhibition of brain gene expression in vivo: experiences targetting the 5-HT1A receptor. Le Corre SM; Burnet PW; Meller R; Sharp T; Harrison PJ Neurochem Int; 1997 Sep; 31(3):349-62. PubMed ID: 9246678 [TBL] [Abstract][Full Text] [Related]
76. Elevated messenger RNA levels after antisense oligodeoxynucleotide treatment in vitro and in vivo. Probst JC; Skutella T Biochem Biophys Res Commun; 1996 Aug; 225(3):861-8. PubMed ID: 8780703 [TBL] [Abstract][Full Text] [Related]
77. Transport of antisense across the blood-brain barrier. Jaeger LB; Banks WA Methods Mol Med; 2005; 106():237-51. PubMed ID: 15375320 [No Abstract] [Full Text] [Related]
78. Development of antisense and antigene oligonucleotide analogs. Miller PS Prog Nucleic Acid Res Mol Biol; 1996; 52():261-91. PubMed ID: 8821263 [No Abstract] [Full Text] [Related]
79. Connexins, Pannexins and Gap Junctions in Perinatal Brain Injury. McDouall A; Zhou KQ; Bennet L; Green CR; Gunn AJ; Davidson JO Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740466 [TBL] [Abstract][Full Text] [Related]
80. Gap Junction Channels of Innexins and Connexins: Relations and Computational Perspectives. Sánchez A; Castro C; Flores DL; Gutiérrez E; Baldi P Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109150 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]